What toxicities related to mirvetuximab have you seen in your patients and how have you managed them?  

Dose-limiting AE’s are fortunately uncommon but need to be addressed as they occur as any other treatment – Grade 2 AE’s can be burdensome to patients particularly, GI toxicity, and following the hold and restart or hold and dose-reduce strategies are critical to making sure indivi...

The most common side effects we experience are ocular and have been relatively well controlled with ocular mitigation strategies and expectation discussions prior to starting.  The most severe adverse event we have experienced is pneumonitis which needs to be recognized with prompt action. Unf...